Munich, Germany

Daniel Nagel



 

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • München, DE (2016)
  • Munich, DE (2017)

Company Filing History:


Years Active: 2016-2017

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: **Daniel Nagel: Innovator in Pharmaceutical Patents**

Introduction

Daniel Nagel, an accomplished inventor based in Munich, Germany, has made significant contributions to the field of pharmaceuticals. With a total of two patents to his name, he has focused on advancing therapeutic applications that address critical health challenges. His innovative mind and dedication to research underscore the importance of his work in the medicinal domain.

Latest Patents

Nagel's latest patents reflect his commitment to enhancing therapeutic options for patients. One notable invention is the patent for the (S)-enantiomer of mepazine. This invention discusses its applicability in therapy, a pharmacological composition comprising (S)-mepazine, and outlines the processes for the preparation of (S)-mepazine and its intermediates. Another significant patent involves the selective inhibition of MALT1 protease by phenothiazine derivatives. This invention addresses compounds for cancer treatment that rely on the proteolytic activity of the MALT1 protease, offering a new avenue for therapeutic intervention in MALT1-dependent immune diseases.

Career Highlights

Throughout his career, Daniel Nagel has been affiliated with prestigious institutions, including the Helmholtz Zentrum München and the Ludwig Maximilians University of Munich. His work at these research centers has enabled him to collaborate with leading experts in the field, further enriching his contributions to pharmaceutical innovations.

Collaborations

Collaboration has played a vital role in Nagel's success as an inventor. He has worked alongside talented individuals such as Daniel Krappmann and Florian Schlauderer, contributing to research that combines diverse expertise and insights. These collaborations have likely fueled innovative ideas and advancements in the area of pharmaceutical patents.

Conclusion

In summary, Daniel Nagel is a notable inventor whose work in pharmaceuticals demonstrates the power of innovation in addressing critical health issues. His patents on the (S)-enantiomer of mepazine and the selective inhibition of MALT1 protease underline his commitment to improving therapeutic options. The connections he has forged during his career only amplify his impact in the field, making him a significant player in the ongoing advancement of medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…